The introduction of biological therapies, i.e., anti-tumor necrosis factor-alpha (TNF-α), anti-α4β7 integrin, and anti-interleukins 12/23 antibodies, caused a revolution in the treatment of IBD; however, they reduced hospitalization, complications, and surgery only in the short- and medium-term. This evidence concerns the gene TNF and inflammatory bowel disease.